Aimns-To assess a commercial enzyme inimunoassay (EIA) for the serotyping of hepatitis C virus (HCV) for routine use in a diagnostic laboratory setting, as well as for noting the serotype prevalence of selected specimens. Methods-Seventy six serum specimens, submitted to the laboratory for routine hepatitis studies between May 1992 and February 1996 and stored at -20°C, were evaluated. These specimens were categorised into specific hepatic, renal, and paediatric clinical conditions. The specimens all tested positive for HCV antibodies on a screening EIA, with confirmation on a recombinant immunoblot assay (RIBA). Certain specimens were also HCV RNA positive by the reverse transcription polymerase chain reaction (RT-PCR). All the specimens were serotyped using the newly developed serotyping EIA. Results-Twenty seven (35.5%) specimens were typable. Type 5 predominated (56%), followed by type 1 (33%), types 1 and 6 (7%) and type 3 (4%). The serotype 5 specimens showed 85% and 90% reactivity with recombinant antigens c100-3 and c22-3c, respectively; serotype 1 specimens showed 75% and 100% reactivity with these antigens. All serotype 5 specimens reacted with the c33-c antigen, but only 60% of serotype 1 specimens reacted with this antigen. The differences in the reactivity of the serotype 5 and serotype 1 specimens for c33-c antigen in the RIBA were significant, but no significant differences in reactivity for antigens c-i-i, c100-3, and c22-3 were noted. Serotype 3 specimens showed equal reactivity with all four antigens used in the RIBA. Conclusion-The serotyping EIA was easy to use, rapid, and cost effective compared with molecular assays. This assay seems to be ideal for the routine diagnostic laboratory setting, but could not be used for certain clinical specimens. The demonstration of serotypes 5, 1, and 3 was not unexpected in this cohort. The occurrence of serotype 6, although concurrent and more likely to be a false cross reaction with serotype 1 peptides, requires confirmation by molecular genotyping before it can be claimed that this type is present in South Africa. (7 Clin Pathol 1996;49:994-997) 
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Hepatitis C virus (HCV) has a seroprevalence of 0.5% to 8.0% among blood donors in many regions of the world, and is also a major aetiological agent of community acquired non-A, were included in the study. After initial screening all specimens were stored at -20°C with limited freeze-thawing. All specimens had tested positive for antibodies to HCV on a screening EIA (Murex anti-HCV, Murex Diagnostics Ltd, Dartford, Kent, UK) and the seropositivity was confirmed on a recombinant immunoblot assay (RIBA) (Chiron RIBA HCV 2.0 SIA; Chiron Corporation, Emeryville, California, USA). Seven of the 76 specimens were tested and found to be positive for HCV RNA by a reverse transcription polymerase chain reaction (RT-PCR) (HCV Probe/Primer Set, Digene Diagnostics Inc, Beltsville, Maryland, USA). The specimens were from patients in the following clinical categories: hepatoma (n = 8), chronic active hepatitis (CAH) (n = 26), acute hepatitis (n = 5), liver cirrhosis (n = 8), renal transplantation follow up (n = 9), pre-renal transplantation assessment (n = 1), chronic haemodialysis (n = 4), nephrotic syndrome (n = 1), a staff member working in a haemodialysis unit (n = 1), and paediatric conditions (n = 2). Eleven of the 76 serum specimens were serial follow up specimens. All specimens were serotyped using a newly developed commercial serotyping EIA (Murex HCV serotyping 1-6 assay). The assay was performed and interpreted strictly according to the manufacturer's instructions. This serotyp- region (c-22-3 ) and the NS3 region (c33-c), respectively, of the genome, which is known to be highly conserved among all serotypes," yet had a lower percentage reactivity with the other non-structural regions. Only the serotype 5 reactivity with antigen c33-c was significantly greater than the serotype 1 reactivity with antigen c33-c. One of the serotype 5 specimens had a low response to the c33-c and clOO-3 antigens. Serotype 1 also had a relatively high prevalence (33%) and was seen in most of the selected clinical categories. Most of the serotype 1 positive patients had antibodies to the NS4 encoded antigens which correlates with findings from earlier studies.8 15 Serotype 3 was detected in only one (4%) of the specimens and displayed uniform reactivity to the recombinant antigens. The low prevalence of this type in the South African community, albeit from a different geographical region, has been noted before.2
Evidence of mixed infection with more than one serotype-that is, serotypes 1 and 6-was seen in a 35 year old woman with CAH and a five year old who presented with liver cirrhosis. This phenomenon has been documented in blood donors from Hong Kong.8 Only retrospective clinical details of the former patient were available; consequently contact with sources other than South African cannot be excluded. The five year old patient, however, was of African ethnic origin, but no HCV relevant risk factors were reported in the clinical history. However, the serotype 6 reactivity in the above two cases is more likely to have been caused by a false cross reaction with the serotype 1 peptides. Therefore, the presence of serotype 6 infection needs to be confirmed by molecular genotyping before it can be concluded that this serotype occurs in the South African population. Serotyping, although one of the important predictors for HCV infection response to treatment, should not be considered in isolation, but in conjunction with the clinical and other laboratory variables determined for each individual patient. The serotyping assay used in this investigation was easy to use in a routine diagnostic laboratory setting. The assay was cost effective, being half the cost of molecular methods. The turnround time of the molecular methods involved three working days; the serotyping assay could be performed within three and a half hours. Although there are limitations to the assay-namely, the inability to differentiate subtypes and reduced sensitivity on stored specimens, it provides a viable alternative to molecular based assays.
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